SHORT-TERM TUMOR RESPONSE TO TYROSINE KINASE INHIBITORS VERSUS LONG-TERM SURVIVAL IN MAST CELL TUMORS: FOLLOW-UP DATA FROM A PIVOTAL FIELD STUDY WITH MASITINIB

摘要

In oncology, clinical studies often use short-term tumor responses as surrogate end-points for survival. A two-year follow-up from a pivotal filed study evaluating masitinib, a tyrosine kinase inhibitor (TKI) targeting c-Kit, for canine mast cell tumors (MCT) allowed analyzing the predictivity of short-term tumor responses for survival.